Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation
Colossal Biosciences is reportedly in talks to raise new capital at a valuation between $20 billion and $30 billion, up from its previous valuation of $10.2 billion. The startup, known for its de-extinction projects, has begun generating revenue and has multiple revenue streams, including partnerships with the U.S. government and the UAE. The company aims to reintroduce extinct species and may generate revenue through biodiversity credits in the future.